Pfizer to make major investment in vaccine R&D and manufacturing site in New York
It’s been just over a month since Pfizer announced it was pumping $120 million into its Michigan facility to boost Paxlovid production, and now the Big Pharma is making another major investment in vaccine manufacturing, this time in its facility outside New York City.
According to a report from Bloomberg, Pfizer is looking to sink $470 million into expanding its vaccine research facilities at its location in Pearl River, NY, just 25 miles north of New York City. Pfizer will construct a new building as well as renovate existing facilities on the campus. The total expansion will be 260,000 square feet with an additional 55,000 square feet of lab space. The company is aiming for construction in the first quarter of 2026, the report said.
According to the company, the Pearl River location has been a hub for its vaccine R&D and was key in the partnership with BioNTech that resulted in their historic Covid-19 vaccine. The research for Prevnar 13 and Trumenba was also conducted there, as well as the manufacture of its antibody-drug conjugates.
The 330-acre site also has more than 800 employees.
An expansion at Pearl River has been on CEO Albert Bourla’s mind for a while now.
In an interview with the Wall Street Journal in 2021, he initially planned to grow the R&D team there by at least 50.
Bloomberg also noted that Pfizer had recently made a separate $29 million investment to establish a lab in Pearl River to study dangerous infectious agents.
This also comes at a time when Pfizer placed a large investment into its 1,300-acre manufacturing facility in Kalamazoo to enable US-based production in support of its Covid-19 oral antiviral. The investment expanded the production of the API and RSMs used in the manufacture of nirmatrelvir, a key component in Paxlovid, and opened up around 250 jobs.